```html

Discoid Lupus Erythematosus (DLE) – A Complete Patient Guide

Overview

Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous (skin‑limited) lupus. It presents as round, disc‑shaped lesions that are typically red, scaly, and can lead to permanent scarring. Unlike systemic lupus erythematosus (SLE), DLE usually stays confined to the skin, although up to 10–20 % of people with DLE may later develop systemic disease.

Who it affects

• Age: Most diagnoses occur between the ages of 20 and 40, but children and older adults can be affected.
• Sex: Women are about 3–4 times more likely to develop DLE than men, mirroring the female predominance seen in other lupus forms.
• Ethnicity: Higher prevalence in people of African, Asian, and Hispanic descent; lower rates in people of Northern European ancestry.

Prevalence

Cutaneous lupus (including DLE) affects roughly 4–5 per 100,000 people in the United States each year<sup>[1]</sup>. DLE accounts for about 75 % of those cases, making it the most frequent isolated skin manifestation of lupus.

Symptoms

DLE lesions can appear on any body surface but prefer sun‑exposed areas. Below is a detailed symptom list:

• Round, disc‑shaped plaques – Typically 0.5–5 cm in diameter with sharply defined borders.
• Redness (erythema) – The base of the plaque is often pink to deep red.
• Scaling and hyperkeratosis – Thick, adherent scales that may be silvery or brownish.
• Follicular plugging – Small keratin plugs that give the surface a “carpet‑tack” appearance.
• Atrophy and scarring – After inflammation resolves, lesions often leave shiny, thinned skin, pigment loss (hypopigmentation), or dark patches (hyperpigmentation).
• Hair loss (alopecia) – When lesions involve the scalp, they can cause permanent hair loss in the affected area.
• Itching or burning sensation – Pruritus is common, especially after sun exposure.
• Sensitivity to sunlight (photosensitivity) – UV light triggers flare‑ups within hours to days.
• Ear involvement – The helix and anti‑helix of the ear are classic sites.
• Oral lesions – Rare, but painless white or red patches may appear on the palate or buccal mucosa.

Causes and Risk Factors

Underlying cause

DLE is an autoimmune disease. The immune system erroneously targets components of the skin, producing auto‑antibodies (especially anti‑Ro/SSA and anti‑La/SSB) that trigger inflammation. Genetic susceptibility, environmental triggers (particularly ultraviolet radiation), and hormonal factors all interact to initiate disease.

Risk factors

• Genetics: First‑degree relatives with lupus or other autoimmune diseases increase risk.
• Skin phototype: Lighter skin types tend to develop more noticeable lesions; darker skin may have more pigment changes.
• Sun exposure: Cumulative UV‑A and UV‑B exposure is the strongest environmental trigger.
• Smoking: Increases lesion severity and reduces response to topical therapy<sup>[2]</sup>.
• Hormonal influences: Female sex hormones (estrogen) may exacerbate autoimmunity; disease often flares during menstrual cycles or pregnancy.
• Medications that cause “drug‑induced” lupus – Certain drugs (e.g., procainamide, hydralazine) can provoke lupus‑like skin lesions, though these are usually reversible after stopping the medication.

Diagnosis

DLE is diagnosed through a combination of clinical evaluation, skin examination, and laboratory testing.

Clinical assessment

• Physical exam focusing on lesion morphology, distribution, and signs of scarring.
• Detailed history of photosensitivity, medication use, and family history of autoimmune disease.

Skin biopsy

A 4‑mm punch biopsy from the active edge of a lesion is the gold‑standard. Histology typically shows:

• Interface dermatitis (damage at the dermo‑epidermal junction).
• Thickened basement membrane.
• Deposition of IgG, IgM, and complement components (C3) along the epidermal basement zone (“lupus band test”).

Laboratory tests

• Antinuclear antibody (ANA): Positive in 20–30 % of DLE patients; a negative ANA makes systemic involvement less likely.
• Anti‑Ro/SSA and anti‑La/SSB: May be present in 10–15 % and can herald progression to systemic disease.
• Complete blood count, renal panel, and urinalysis to screen for silent systemic involvement.

Imaging (rarely needed)

If systemic lupus is suspected, chest X‑ray or echocardiography may be ordered, but these are not routine for isolated DLE.

Treatment Options

Treatment goals are to control inflammation, prevent scarring, and minimize photosensitivity. A step‑wise approach is usually employed.

Topical therapies

• High‑potency corticosteroids (clobetasol 0.05 %): First‑line for active plaques; apply thinly once daily for 2–4 weeks.
• Calcineurin inhibitors (tacrolimus 0.1 % ointment or pimecrolimus 1 % cream): Useful for steroid‑sparing, especially on the face or neck.
• Intralesional steroid injections (triamcinolone acetonide 10 mg/mL): For thick, resistant plaques.

Systemic medications

Reserved for extensive disease, scalp involvement, or lesions unresponsive to topical agents.

• Antimalarials – Hydroxychloroquine 200–400 mg daily is the cornerstone; proven to reduce new lesions in >70 % of patients<sup>[3]</sup>. Baseline and annual ophthalmologic exams are mandatory.
• Systemic corticosteroids – Short courses of oral prednisone (≤10 mg/day) for acute flares.
• Immunosuppressants – Methotrexate, azathioprine, or mycophenolate mofetil for refractory cases.
• Biologic agents – Belimumab (anti‑BLyS) and rituximab have emerging evidence in severe cutaneous lupus; usually considered after failure of conventional therapy.

Procedural options

• Laser therapy – Fractional CO₂ laser can improve scarring and persistent hyperpigmentation.
• Phototherapy (PUVA) – Generally avoided in DLE because UV can worsen disease; only used under strict supervision for select patients.
• Sun protection measures (see Lifestyle section) – Not a medication but essential to treatment success.

Lifestyle and adjunct measures

• Broad‑spectrum sunscreen SPF ≥ 30 applied 15 minutes before sun exposure; reapply every 2 hours.
• Protective clothing (wide‑brim hats, UV‑blocking fabrics).
• Smoking cessation – improves response to antimalarials.
• Stress‑management techniques (mindfulness, yoga) – stress can trigger flares.

Living with Discoid Lupus Erythematosus

Daily skin care

• Use gentle, fragrance‑free cleansers; avoid abrasive scrubs.
• Moisturize twice daily with emollients containing ceramides or hyaluronic acid to maintain barrier function.
• Do not pick or scratch lesions – this increases scarring risk.

Sun management

• Seek shade between 10 am–4 pm when UV intensity peaks.
• Apply sunscreen even on cloudy days.
• Consider UV‑protective window films at home or in the car.

Monitoring your disease

• Keep a symptom diary: note new lesions, flare triggers, and medication side effects.
• Schedule dermatology visits every 3–6 months, or sooner if lesions change.
• Annual blood work and eye exams if you’re on hydroxychloroquine.

Psychosocial support

Visible skin lesions can affect self‑esteem. Consider joining a lupus support group, counseling, or online communities (e.g., Lupus Foundation of America). Peer support improves coping and adherence to treatment.

Prevention

While you cannot change genetic predisposition, several actions lower the chance of developing DLE or prevent disease progression:

• Consistent sun protection (sunscreen, clothing, hats).
• Avoid tobacco products.
• Maintain a balanced diet rich in omega‑3 fatty acids (fish, flaxseed) – anti‑inflammatory effect.
• Limit alcohol if taking medications that affect liver function (hydroxychloroquine, methotrexate).
• Promptly treat any rash or skin irritation before it becomes chronic.

Complications

If DLE is untreated or poorly controlled, complications may include:

• Permanent scarring and disfiguring atrophy, especially on the face or scalp.
• Permanent hair loss (alopecia) when scalp lesions destroy hair follicles.
• Secondary infection of open plaques.
• Progression to systemic lupus erythematosus – estimated 10–20 % risk, especially in those with positive ANA or anti‑Ro/SSA antibodies.
• Psychological impact – depression or anxiety related to cosmetic concerns.
• Medication toxicity – Long‑term steroid use can cause osteoporosis, hypertension, or diabetes; antimalarial retinal toxicity (rare, <1 %) requires monitoring.

When to Seek Emergency Care

References

1. Wallace, D.J., et al. “Cutaneous Lupus Erythematosus: Epidemiology and Clinical Features.” J Am Acad Dermatol, 2018; 78(2): 227‑235.
2. Cleveland Clinic. “Lupus – Symptoms, Causes, and Treatment.” Accessed June 2024. https://my.clevelandclinic.org/health/diseases/15894-lupus
3. Mayo Clinic. “Lupus treatment: Overview.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/lupus-treatment/diagnosis-treatment/drc-20365795
4. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Discoid Lupus.” 2024. https://www.niams.nih.gov/health-topics/discoid-lupus
5. World Health Organization. “Autoimmune diseases: global burden.” 2022.

```